Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; tryptophan, quantity: 1.9 g/l; methionine, quantity: 5.6 g/l; isoleucine, quantity: 5.6 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - glucose, quantity: 500 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections; sodium bicarbonate - glucose 50% intravenous infusion is strongly hypertonic and may be used to reduce increased cerebrospinal pressure and/or oedema due to delirium tremens or acute alcoholic intoxication. it may also be used to treat severe hypoglycaemia due to an excess of insulin and to provide concentrated calories in total parenteral nutrition regimes.